Merus N.V. (FRA:2GH)

Market Cap	6.27B
Revenue (ttm)	48.25M
Net Income (ttm)	-324.84M
Shares Out	n/a
EPS (ttm)	-4.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	80.50
Previous Close	80.50
Day's Range	80.50 - 80.50
52-Week Range	29.40 - 82.50
Beta	n/a
RSI	53.43
Earnings Date	Feb 27, 2026

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumor...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 321
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2GH

Financial Performance

In 2024, Merus's revenue was $36.13 million, a decrease of -17.78% compared to the previous year's $43.95 million. Losses were -$215.33 million, 39.0% more than in 2023.

Financial numbers in USD